Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...

SmartScripts has faced a welter of lawsuits and been fined for its sale of a counterfeit version of popular weight-loss drug Ozempic.

The rise of a grey market in India, where unsupervised doses are sold at exorbitant rates, demonstrates that excessive ...

Novo Nordisk A/S ( NVO) trimmed its forecast for a fourth time this year on Wednesday, citing lower-than-expected sales of ...

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.

The kilo-shedding jabs can lead to ‘Ozempic face’ and make you look gaunt. Experts reveal how to minimise your risk and ...

People looking to lose weight and lower their blood sugar may someday be able to get a single injection that turns their ...

The latest of those is a bid valued at up to $10 billion for U.S. obesity-drug developer Metsera, up from a previous $9 billion offer it originally made, as it tries to usurp an already agree-on deal ...